B

Best Skin Research, LLC. | Camp Hill, PA

Research site

(Unclaimed)

Location

207 House Avenue, Suite 102, Camp Hill, Pennsylvania, United States of America

Site insights

Top conditions

Top treatments

RO7790121

Deucravacitinib

Rocatinlimab

Ustekinumab

Ruxolitinib

Afimkibart

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 5 total trials

A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis (Velarite-LTE)

This study will assess long-term safety and efficacy of Afimkibart (also known as RO7790121) in participants with Atopic Dermatitis (AD) who particip...

Enrolling

Atopic Dermatitis

Drug: Afimkibart

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND)

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Active, not recruiting

Atopic Dermatitis

Other: Placebo

Drug: Rocatinlimab

A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis

The purpose of this study is to assess the efficacy and safety of Afimkibart (also known as RO7790121) in participants with moderate to severe atopic...

Enrolling

Atopic Dermatitis

Drug: Afimkibart

Drug: Placebo